334 related articles for article (PubMed ID: 36514850)
1. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
[TBL] [Abstract][Full Text] [Related]
3. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Suleiman AA; Khatri A; Oberoi RK; Othman AA
Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
Morita A; Okubo Y; Morisaki Y; Torisu-Itakura H; Umezawa Y
Dermatol Ther (Heidelb); 2022 Feb; 12(2):481-494. PubMed ID: 34967916
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Okubo Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1397-1415. PubMed ID: 35622315
[TBL] [Abstract][Full Text] [Related]
7. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S; Okubo Y; Tada Y; Ohtsuki M; Colston E; Napoli A; Shao Y; Banerjee S; Morita A
J Dermatol; 2024 Mar; 51(3):365-379. PubMed ID: 38268101
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
15. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
[TBL] [Abstract][Full Text] [Related]
16. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study.
Morita A; Yamazaki F; Matsuyama T; Takahashi K; Arai S; Asahina A; Imafuku S; Nakagawa H; Hasegawa Y; Williams D; Matsuda N; Kitamura S
J Dermatol; 2018 Dec; 45(12):1371-1380. PubMed ID: 30302793
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
[TBL] [Abstract][Full Text] [Related]
19. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
20. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
